Drugs / lipiodol
lipiodol
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | LIPIODOL | — | 2014-04-04 | fda.gov ↗ |
| Approved | US (FDA) | LIPIODOL | — | 1954-03-31 | fda.gov ↗ |
Trials 9 · a red edge is where a trial was stopped
195319541955195619571958195919601961196219631964196519661967196819691970197119721973197419751976197719781979198019811982198319841985198619871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027202820292030
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05490381 | Dec 2023 → Jan 2025 | head and neck cancer | University of Washington | Withdrawn | No outcome recorded |
| Phase 1 | NCT04733092 | Mar 2021 → Jun 2022 | osteoarthritis, knee | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05340231 | May → Dec 2022 | colorectal cancer | Gang Wu | Unknown | No outcome recorded |
| Phase 2 | NCT01877187 | Apr 2013 → Feb 2020 | liver cancer | Yale University | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT06497140 | Sep 2024 → Jan 2028 expected | osteoarthritis, knee | Assistance Publique - Hôpitaux de Paris | Recruiting | No outcome recorded |
| Phase 3 | NCT03542331 | Mar 2018 → Jan 2020 | female infertility | University Hospital Brussels | Unknown | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT04379973 | May 2021 → Jun 2027 expected | female infertility | Dafne Balemans | Active not recruiting | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT03277716 | Dec 2017 → Dec 2019 | hepatocellular carcinoma | Fan Weijun | Unknown | No outcome recorded |
| — | NCT02180568 | May 2014 → Dec 2016 | lung disorder | Severance Hospital | Completed | No outcome recorded |
Also used as a comparator or background therapy in 36 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT07295262 Background | Jan 2026 → Jul 2028 expected | adult hepatocellular carcinoma | West China Hospital | Recruiting | No outcome recorded |
| Phase 0 | NCT04753918 Background | Mar → Sep 2021 | non-small cell lung carcinoma | Taoyuan General Hospital | Unknown | No outcome recorded |
| Phase 0 | NCT04048317 Comparator | Sep 2019 → Sep 2020 | hepatocellular carcinoma | Assiut University | Unknown | No outcome recorded |
| Phase 13 trials | ||||||
| Phase 1 | NCT07132541 Background | Aug 2025 → Aug 2026 overdue | ampulla of vater cancer, malignant pancreatic neoplasm | Minia University | Recruiting | No outcome recorded |
| Phase 1 | NCT04200417 Background | Dec 2019 → Apr 2022 | bronchial neoplasm, mediastinal cancer, pleural neoplasm, respiratory system cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT03865563 Background | Jul 2019 → Jun 2021 | pancreatic adenocarcinoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Withdrawn | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT05842174 Background | Apr 2026 → Sep 2029 expected | hepatocellular carcinoma | VA Office of Research and Development | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05435014 Comparator | Sep 2022 → Jun 2026 | hepatocellular carcinoma | T-ACE Medical Co., Ltd | Suspended | No outcome recorded |
| Phase 1/2 | NCT02638857 Background | Sep 2015 → Mar 2017 | hepatocellular carcinoma | Second Military Medical University | Unknown | No outcome recorded |
| Phase 29 trials | ||||||
| Phase 2 | NCT07380633 Comparator | Jan 2026 → Dec 2027 expected | hepatocellular carcinoma | Sun Yat-sen University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT07230509 Background | Dec 2025 → Dec 2027 expected | ampulla of vater cancer, malignant pancreatic neoplasm | Minia University | Recruiting | No outcome recorded |
| Phase 2 | NCT05672108 Background | May 2023 → Oct 2027 expected | bronchial neoplasm, colon carcinoma, neoplasm of mediastinum, non-small cell lung carcinoma +2 | City of Hope Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT05361161 Background | Jun → Dec 2022 | gastric cancer | Gang Wu | Unknown | No outcome recorded |
| Phase 2 | NCT04728633 Background | Sep 2021 → Jan 2027 expected | metastatic malignant neoplasm, uveal melanoma | Thomas Jefferson University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03727633 Background | Jul 2018 → Jun 2025 | hepatocellular carcinoma | University Hospital, Montpellier | Terminated | No outcome recorded |
| Phase 2 | NCT03511703 Background | May → Dec 2018 | hepatocellular carcinoma | Guangxi Medical University | Unknown | No outcome recorded |
| Phase 2 | NCT03048123 Comparator | Oct 2015 → Oct 2016 | hepatocellular carcinoma | Sun Yat-sen University | Completed | No outcome recorded |
| Phase 2 | NCT00820053 Background | Jan → Dec 2009 | hepatocellular carcinoma | Eastern Hepatobiliary Surgery Hospital | Completed | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT02585479 Comparator | Oct 2015 → Oct 2017 | hepatocellular carcinoma | Guangxi Medical University | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT02584556 Background | Oct 2015 → Oct 2017 | hepatocellular carcinoma | Guangxi Medical University | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT01861912 Background | Jun 2013 → Jun 2016 | hepatocellular carcinoma | Guangdong Provincial People's Hospital | Unknown | No outcome recorded |
| Phase 39 trials | ||||||
| Phase 3 | NCT06130072 Comparator | Nov 2023 → Mar 2024 | — | Ain Shams University | Unknown | No outcome recorded |
| Phase 3 | NCT05647954 Background | Dec 2022 → Dec 2024 | neuroendocrine neoplasm | Taizhou Hanzhong Biomedical Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT03192644 Comparator | Jul 2017 → Dec 2022 | hepatocellular carcinoma | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 3 | NCT02971345 Background | Jan 2017 → Oct 2020 | hepatocellular carcinoma, portal vein thrombosis | Shanghai Zhongshan Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT02762266 Comparator | Feb 2016 → Dec 2022 | hepatocellular carcinoma | Stanford University | Terminated | No outcome recorded |
| Phase 3 | NCT02630108 Background | Dec 2015 → Dec 2017 | hepatocellular carcinoma | Shanghai Zhongshan Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT02109146 Background | Mar 2014 → May 2023 | hepatocellular carcinoma | Zhejiang University | Completed | No outcome recorded |
| Phase 3 | NCT02755311 Comparator | Mar 2014 → Jun 2016 | hepatocellular carcinoma | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 3 | NCT00470340 Background | Jun 2007 → Nov 2008 | cirrhosis of liver, hepatocellular carcinoma | Assistance Publique - Hôpitaux de Paris | Terminated | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT02631499 Background | Dec 2015 → Dec 2018 | hepatocellular carcinoma | Fudan University | Unknown | No outcome recorded |
| Phase 4 | NCT01959061 Background | Sep 2013 → Dec 2017 | colorectal cancer | Nanjing Chia-tai Tianqing Pharmaceutical | Unknown | No outcome recorded |
| Phase not applicable4 trials | ||||||
| — | NCT03617029 Comparator | Jan → Oct 2019 | lung cancer | National Taiwan University Hospital Hsin-Chu Branch | Unknown | No outcome recorded |
| — | NCT01923064 Comparator | Oct → Dec 2013 | portal hypertension | Shanghai Zhongshan Hospital | Completed | No outcome recorded |
| — | NCT01489410 Comparator | Oct 2012 → Mar 2014 | hepatocellular carcinoma | University of Minnesota | Withdrawn | No outcome recorded |
| — | NCT00825669 Comparator | Dec 2008 → Dec 2009 | hepatocellular carcinoma | Eastern Hepatobiliary Surgery Hospital | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 45 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | lipiodol | “Then the left and right hepatic arteries were accessed by a microcatheter and intraarterial epirubicin (40 mg) and oxaliplatin (150 mg) in a mixture of lipiodol (3～5 mL) were injected.” NCT02109146 ↗34“Arterial infusion chemotherapy (THP + oxaliplatin + raltitrexed) and THP combined with lipiodol embolization for 2 times, with an interval of 1 month.” NCT05361161 ↗ “fotemustine 100 mg/sqm, day2, every 6 weeks; lipiodol is usually 5-10 ml (According to the location and number of lesions)” NCT05647954 ↗ “Lipiodol 5-10ml,Pirarubicin17mg/m2 and Oxaliplatin 30mg/m2 are infused through the right and left hepatic arteries” NCT02584556 ↗ “Injection of Histoacryl® (n-butyl-2-cyanoacrylate) mixed with Lipiodol® (1:1 ratio) into the pancreatic parenchyma” NCT07132541 ↗ “Injection of Histoacryl® (n-butyl-2-cyanoacrylate) mixed with Lipiodol® (1:1 ratio) into the pancreatic parenchyma” NCT07230509 ↗ “The chemotherapeutic drugs and 2 to 10 ml lipiodol are given via hepatica propria artery.” NCT00825669 ↗ “Self-assembled nanoprobes of Indocyanine Green (ICG) and Cisplatin mixed with lipiodol” NCT07295262 ↗ “Chemoembolization: Lipiodol emulsion (lipiodol 10ml+ Oxaliplatin 85mg +Lidocaine 1ml)” NCT05340231 ↗ “300mg/m2 carb mixed with 2-5 mL lipiodol, followed by pure lipiodol” NCT07380633 ↗ “lipiodol mixed with chemotherapy drugs (EADM, lobaplatin, and MMC)” NCT03048123 ↗ “Embolic agent: lipiodol and embolic microspherea” NCT03277716 ↗ |
| Known as | Ethiodized Oil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05490381 ↗ |
| Known as | Iodized oil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03511703 ↗ |
| Known as | Lipidol | “iso-amyl- 2-cyanoacrylate mixed with Ethiodized oil (Lipidol)” NCT06130072 ↗ |
| Known as | Lipiodol Ultra-Fluide | “Chemolipiodolization was performed mixed with 5 ml of lipiodol (Lipiodol Ultra-Fluide; André Guerbet Laboratories, Aulnay-sous-Bois, France).” NCT02755311 ↗ |
| Known as | Ultra-fluid lipiodol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02971345 ↗ |
| Modality | Diagnostic / imaging agent | “oil-soluble contrast medium (OSCM)” NCT04379973 ↗ |
| Route | Intrathecal | “intra-arterial chemotherapy (CIAL = cisplatin 75 mg + lipiodol 10 ml)” NCT00470340 ↗ |